1. Home
  2. SSTK vs FULC Comparison

SSTK vs FULC Comparison

Compare SSTK & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shutterstock Inc.

SSTK

Shutterstock Inc.

HOLD

Current Price

$17.38

Market Cap

596.1M

Sector

Technology

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$7.48

Market Cap

535.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSTK
FULC
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
596.1M
535.5M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
SSTK
FULC
Price
$17.38
$7.48
Analyst Decision
Buy
Buy
Analyst Count
2
8
Target Price
$25.00
$16.38
AVG Volume (30 Days)
194.0K
916.8K
Earning Date
04-28-2026
04-27-2026
Dividend Yield
8.17%
N/A
EPS Growth
23.76
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.35
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.36
$3.55
52 Week High
$29.50
$15.74

Technical Indicators

Market Signals
Indicator
SSTK
FULC
Relative Strength Index (RSI) 50.64 44.20
Support Level $15.88 $7.40
Resistance Level $17.81 $8.24
Average True Range (ATR) 0.52 0.48
MACD -0.00 0.00
Stochastic Oscillator 41.19 30.51

Price Performance

Historical Comparison
SSTK
FULC

About SSTK Shutterstock Inc.

Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: